PT  - JOURNAL ARTICLE
AU  - Sazdanovic, Predrag S.
AU  - Milisavljevic, Slobodan
AU  - Milovanovic, Dragan R.
AU  - Jankovic, Slobodan M.
AU  - Baskic, Dejan
AU  - Ristic, Dragana Ignjatovic
AU  - Zecevic, Dejana Ruzic
AU  - Lucic, Aleksandra Tomic
AU  - Djordjevic, Natasa
AU  - Jovanovic, Danijela
AU  - Stojkovic, Andjelka
AU  - Lazarevic, Tatjana
AU  - Cvetkovic, Milica Begovic
AU  - Kostic, Marina J.
TI  - TREATMENT COSTS FOR COVID-19 PATIENTS IN A TERTIARY HOSPITAL FROM SERBIA
AID  - 10.1101/2021.11.30.21267085
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.11.30.21267085
4099  - http://medrxiv.org/content/early/2021/12/02/2021.11.30.21267085.short
4100  - http://medrxiv.org/content/early/2021/12/02/2021.11.30.21267085.full
AB  - Introduction Aim of our study was to identify total costs of COVID-19 inpatients treatment in an upper-middle income country from Southeast Europe.Methods This retrospective, observational cost of illness study was performed from National Health Insurance Fund perspective and included a cohort of 118 males and 78 females admitted to COVID-19 ward units of a tertiary center, during the first wave of epidemics.Results The median of total costs in the non-survivors’ subgroup (n=43) was 3279.16 Euro (4023.34, 355.20, 9909.61) which is higher than in the survivors (n=153) subgroup 747.10 Euro (1088.21, 46.71, 3265.91). The odds ratio of Charlson Comorbidity Index total score and every 100-Euros increase of patient’s total hospital treatment costs for fatal outcome were 1.804 (95% confidence interval 1.408-2.311, p<0.001) and 1.050 (1.029-1.072, p<0.001), respectively.Conclusions Direct medical treatment costs for COVID-19 inpatients represent significant economic burden. The link between increased costs and unfavorable final outcome should be further explored.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe research was partially supported by the grant of The Ministry of Education, Science and Technological Development of the Republic of Serbia No175007.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Institutional Ethics Committee of University Clinical Centre Kragujevac, Serbia, and conducted according to principles of Declaration of Helsinki (Decision of the Ethics Committee number 01/20-407, dated April 3rd 2020).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Yesll data produced in the present work are contained in the manuscript